ArticleBMC gastroenterology2025
WeChat-based manual enhanced guidance in patients with Helicobacter pylori infection.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPatients' adherence is important for successful Helicobacter pylori (H. pylori) eradication, and may be improved by WeChat, a popular social networking platform. This study aimed to evaluate patients' adherence, successful H. pylori eradication, and clinical remission under the WeChat-based enhanced guidance.
methodsNinety-nine patients with H. pylori infection, who were treated by a 14-day standard bismuth-containing quadruple therapy (BQT) and received the WeChat-based enhanced guidance, were retrospectively included. Multivariate logistic regression analysis was performed to identify independent predictors of patients' adherence and H. pylori eradication. Odds ratios (ORs) were calculated.
resultsThe rates of good medication adherence, good re-examination adherence, successful H. pylori eradication, and clinical remission were 97.0%, 83.8%, 89.2%, and 89.5%, respectively. Patients with poor re-examination adherence had significantly lower proportions of individual dining (13.3% versus 50.6%, P=0.008) and no smoking during treatment (66.7% versus 92.8%, P=0.012) than those with good re-examination adherence. Both individual dining (OR=0.182, P=0.035) and no smoking during treatment (OR=0.210, P=0.031) were independently associated with good re-examination adherence. Patients with H. pylori eradication failure had significantly higher proportions of poor medication adherence (22.2% versus 1.4%, P=0.030) and living in rural area (44.4% versus 8.1%, P=0.009) than those with H. pylori eradication success. Both poor medication adherence (OR=20.366, P=0.031) and living in rural area (OR=8.944, P=0.010) were independently associated with H. pylori eradication failure.
conclusionThere is good medication adherence with satisfactory H. pylori eradication and clinical remission under the WeChat-based enhanced guidance. How to improve re-examination adherence should be further explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.